Page 9 - Bio Developments News Today

CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of novel cell therapies, has announced a £7.6 million seed round.

In a significant move in December 2023, Roche completed the acquisition of the US-based company Carmot Therapeutics in a deal worth $2.9 billion.

Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a phase 1 trial of I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma.

On January 8, Amgen presented at JP Morgan’s 42nd Annual Healthcare Conference 2024 (JPM24), highlighting its pillars of business.

Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view:

We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.

WuXi AppTec has commissioned two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.

Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.

AGC Biologics has announced plans to construct a new manufacturing facility at its existing Yokohama technical center in Japan.

Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).